Icotinib Hydrochloride
CAS: 1204313-51-8
Ref. TM-T2307
5mg | 60.00 € | ||
10mg | 87.00 € | ||
25mg | 138.00 € | ||
50mg | 223.00 € | ||
100mg | 330.00 € | ||
200mg | 491.00 € | ||
1ml*10 (DMSO) | 66.00 € |
Product Information
- BPI-2009H
Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.
Chemical properties
Technical inquiry about: TM-T2307 Icotinib Hydrochloride
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.